Population
Patients with heart failure
Design
Review
Authors
Loading...
Broadens RAS blockade rationale in HF beyond hemodynamics; leaves open whether targeting neuroendocrine or gene effects improves outcomes.
This review highlights that ACE-inhibition in heart failure provides benefits beyond vasodilation by attenuating neuroendocrine activity and preventing adverse myocardial remodeling.
J. Holtz (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: